Similar in vivo results have also been reported in T2D patients treated with GLP-1 agonist30 although long-term randomized clinical trials using incretin-based therapies (GLP-1 agonist or DPP4-inhibitors) have reported neutral effects31, 32. Here, DPP4 is linked to type 2 diabetes mellitus.